GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Net Issuance of Preferred Stock

Tourmaline Bio (Tourmaline Bio) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Tourmaline Bio's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. The number is 0, which means that Tourmaline Bio has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Tourmaline Bio's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Tourmaline Bio Net Issuance of Preferred Stock Historical Data

The historical data trend for Tourmaline Bio's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Net Issuance of Preferred Stock Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
- 20.00 91.82

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only - - - - -

Tourmaline Bio Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.